TCF7L2 and Hyperglycemia: Thirdly, from a genetic perspective, Genetic polymorphisms associated with GDM (e.g., TCF7L2, IRS1) in North American populations (particularly those of European ancestry) (66) may intersect with breast cancer protective pathways (e.g., estrogen metabolism), counteracting the carcinogenic effects of hyperglycemia (2, 17).